Collectively, these data (a) demonstrate that endothelial cell-secreted IL-6 defines the tumorigenic potential of CSC; and (b) suggest that HNSCC patients might benefit from the therapeutic inhibition of IL-6/IL-6R signaling [42]. Here, IL6 is linked to head and neck squamous cell carcinoma.